Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Inventiva S.a. IVA

7 fiscal years on record · EUR · FY2024 reported · SEC filings only
€9.2M
▼ 47.4% YoY
€-184.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

EUR 9.2M
Revenue, FY2024 · full 7-year series below
Revenue €M Net income €M
FY2024 · Revenue 9.2 · Net income -184.2
-100M-200M
201820212024
Compound annual growth
+29.9%
+5.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.6% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -1060.6% · Net ·
-2000%-4000%-6000%
201820212024
ROE
FY2022 · ROE -80.8%
-50%
201820212024
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks

Total assetsEUR 119.0M
CashEUR 96.6M
Current ratio0.92×

Not available: we don't have the total debt figure for this period.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · EUR

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IVA, 7-year financial record
Metric 2024202320222021202020192018
Revenue €B0.00.00.00.00.00.00.0
Operating income €B−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA €B◌◌◌◌◌◌◌
Income tax €B0.00.0−0.00.00.00.0◌
Net income €B−0.2−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted €−3.08−2.43−1.31−1.27−0.99−1.28◌
Dividend / sh €◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %——−80.8−49.6−44.1−58.7−53.6
Shares out B0.100.050.040.040.04◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 27 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image